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Background: Ayurveda, the Indian traditional system of medicine describes a unique concept “prakriti”, genetically
determined, categorising the population into several subgroups based on phenotypic characters like appearance,
temperament and habits. The concept is claimed to be useful in predicting an individual’s susceptibility to a
particular disease, prognosis of that illness and selection of therapy. The present study was carried out to study if
the platelet aggregatory response and its inhibition by aspirin varied in the different prakriti subtypes.
Methods: After obtaining Institutional Ethics Committee permission, normal healthy individuals of either sex
between the age group 18 to 30 years were recruited in the study. Their prakriti evaluation was done using a
standardized validated questionnaire (TNMC Prakriti 2004). Their Platelet Rich Plasma was incubated with either
aspirin [2.5micro-mole (μM) and 5μM] or distilled water as control for three minutes after which the aggregatory
response to 5μM Adenosine Diphosphate (ADP) was measured over a period of 7 minutes.
Results: We observed that in the study population of normal healthy participants (n= 137), ADP-induced maximal
platelet aggregation (MPA) was highest among the Vata-pitta prakriti individuals [Median (range), 83.33% (52.33-96)]
as compared to the other prakriti types and these individuals responded better to lower dose of aspirin compared
to other prakriti types.
Conclusions: Our results suggest that identifying the prakriti may help in individualising therapy or predicting
proneness to a disease.
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Ayurveda, the Indian traditional system of medicine [1]
describes a unique concept “prakriti” [2] (constitution),
which is genetically determined, categorising the popula-
tion into several subgroups based on phenotypic charac-
ters like appearance, temperament and habits. The
concept is claimed to be useful in predicting an indivi-
dual’s susceptibility to a particular disease, prognosis of
that illness and selection of therapy [3].
Ayurveda attributes these constitutional characteristics
of an individual to the preponderance of certain
“doshas”. Three main doshas are described, viz. vata,
pitta and kapha. Kapha dosha is the “anabolic”, syn-
thetic dosha, responsible for growth and maintenance of
structure [4]. The pitta dosha is the one responsible for* Correspondence: urmilathatte@kem.edu
2Dept. of Clinical Pharmacology, Seth GS Medical College and KEM Hospital,
Parel, Mumbai 400 012, India
Full list of author information is available at the end of the article
© 2012 Bhalerao et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormetabolism, including digestion in the gut, and cellular
or sub-cellular metabolism. Vata dosha is responsible
for movement (muscular, nervous energy etc.). Based on
the predominance of individual doshas, there are three
major types of prakriti named after predominant dosha,
viz., vata, pitta and kapha. The prakriti is believed to be
determined at the time of conception and is influenced
by the milieu interior of the womb and the dietary habits
and lifestyle of the mother [5]. These prakritis exhibit
attributes of the dominant Dosha in physical, physio-
logical and psychological characteristics. The disturb-
ance in equilibrium of these doshas can lead to disease
according to the prakriti of the person for example; a
pitta prakriti person is described to be more prone to
peptic ulcers, hypertension, and skin diseases, a vata
prakriti person to backache, joint aches and crackling
joints while individuals with kapha prakriti are prone to
obesity, diabetes and atherosclerosis [6-8].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prakriti individuals show specific groupings according to
anthropometric measurements and biochemical variables
like serum cholesterol, blood sugar or blood groups [9].
Recently a study reported complete absence of the HLA
DRB1*02 allele in the Vata type and of HLA DRB1*13 in
the Kapha type. Higher allele frequency of HLA
DRB1*10 was noted in the Kapha type than in the Pitta
and Vata types [10].
In another study, the differences in the whole gene ex-
pression among the various prakriti subtypes have also
been explored. The functional categories of genes show-
ing differential expression among Prakriti types were sig-
nificantly enriched in core biological processes like
transport, regulation of cyclin dependent protein kinase
activity, immune response and regulation of blood co-
agulation. A significant enrichment of housekeeping,
disease related and hub genes were also observed in the
three extreme constitution types [2].
In our earlier studies we found a specific type of prak-
riti was predominant in epileptic or hypertensive indivi-
duals as compared to normal healthy individuals [7].
Platelet reactivity, the phenomenon that markedly
influences the pathological outcome of thrombosis and
sensitivity to anti-platelet drugs, has been reported to
exhibit individual/genetic variations [11]. Since prakriti
has been described to have genetic origin in Ayurvedic
texts [5] we thought it would be interesting to study
whether platelet aggregation in response to ADP and
its inhibition with aspirin varies in the different prakriti
sub-types.Table 1 Demographic details (n=137)Methods
Ethics
The study was initiated after obtaining permission from
Institutional Ethics Committee, BYL Nair Ch. Hospital
& TN Medical College, Mumbai and conducted accord-
ing to the principles enunciated in the Declaration of
Helsinki (2008) [available at http://www.wma.net/en/
30publications/10policies/b3/index.html last accessed on
8th June 2012] and the ICMR’s Ethical Guidelines for
Biomedical Research in Human Participants [available at
http://icmr.nic.in/ethical_guidelines.pdf last accessed on
8th June 2012]. Only those participants who gave written
informed consent were recruited.Prakriti n (M:F) Age (years) BMI (kg/m2)
Vata-Kapha 4 (1:3) 23 ± 1.22 18.99 ± 2.57
Vata-Pitta 16 (7:9) 22.94 ± 2.08 19.71± 2.47*
Pitta-Kapha 65 (32:33) 23.08 ± 1.71 21.81 ± 2.67
Pitta-Vata 12 (7:5) 23.25 ± 2.45 20.37 ± 2.79
Kapha-Vata 4 (1:3) 23.50 ± 2.08 20.34 ± 2.21
Kapha-Pitta 36 (19:17) 23.14 ± 2.28 23.42 ± 3.89
*p<0.05 as compared to Kapha-Pitta using One-way ANOVA.Study population
Normal healthy individuals (confirmed by history, phy-
sical examination and routine laboratory investigations,
including hematology, renal and liver function tests) be-
tween the age group of 18 to 30 years (both years inclu-
sive) of either sex, and willing to abide by trial
procedures were enrolled.Prakriti assessment
Prakriti was assessed using a multiple-choice question-
naire (Additional file 1: TNMC Prakriti 2004) which was
designed on the basis of literature in Ayurvedic texts
comprising 37 objective questions related to the person’s
physical characteristics, psychological make-up and
physiological habits (Table 1). Each of the questions had
three options to choose from referring to a property
attributed to Vata (V), Pitta (P) or Kapha (K). The score
obtained by a person for answers in the V, P and K do-
main were summed up and the person was identified as
having a specific prakriti depending on scores obtained.
When a participant scored ≥ 50% on a particular dosha,
that was considered as the predominant dosha, whereas
a score between 25%- 35% categorised the dosha as the
secondary dosha in the prakriti. For example, when a
participant scored 20 (54%) for the Pitta dosha and 13
(32%) for the Kapha dosha, he was categorised as a
Pitta-Kapha prakriti. On the other hand if the score was
22 (59%) for the Kapha dosha and 12 (32%) for the Pitta
dosha, he was categorised as Kapha-Pitta prakriti.Validation of questionnaire
The questionnaire was validated by pre-testing where the
results obtained by the questionnaire were confirmed by
the clinical assessment of the prakriti independently by
two Ayurveda physicians in 30 participants. More than
90% concordance was observed in the prakriti assessment
by the two clinicians as well as by the questionnaire.Evaluation of prakriti in participants
For the study, the prakriti of each volunteer was assessed
using the validated questionnaire (Additional file 1: TNMC
Prakriti 2004). It was further confirmed by an Ayurvedic
physician (first author) following a traditional algorithm
(based on interview and a physical examination) to assess
various physical, physiological and psychological characters
as described in Ayurvedic texts [5].
The individual was classified into vata-pitta, vata-
kapha, pitta-kapha, pitta-vata, kapha-pitta or kapha-
vata prakriti.
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Platelet aggregatory response to ADP was studied using
the turbidometric method described by Born [12] on a
Chronolog platelet aggregocorder. Briefly, 9ml blood was
collected from each volunteer in a polystyrene tube con-
taining 1 ml of 3.8% sodium citrate. Platelet rich plasma
(PRP) was obtained as a supernatant by centrifugation
(1000 rpm for 10 mins at 25°C) and the remaining blood
was centrifuged again (4000 rpm for 15 mins at 25°C) to
obtain platelet poor plasma (PPP). Platelets in the PRP
were counted using a platelet counter and the count was
adjusted to 2 × 105/L using autologus PPP for dilution.
This plasma was incubated with either aspirin (2.5μM
and 5μM) or distilled water as control for three minutes
after which the aggregatory response to 5μM Adenosine
Diphosphate (ADP) was measured over a period of 7
minutes. The percent aggregation at this time point was
defined as the Maximal Platelet Aggregation (MPA).
dMPA was calculated by subtracting % MPA with aspirin
from % MPA with distilled water.
Reproducibility of platelet aggregation studies
Platelet aggregation studies were repeated thrice at an
interval of 15 days in the initial 76 participants to iden-
tify whether there was variability in platelet aggregation
over a period of time. Results suggested that there was
no significant variation in platelet function over time
and hence platelet aggregation was studied only once in
the rest of the participants (n=61). The average of the
three readings of the initial 76 participants was used for
analysis.
Statistical analysis
In the absence of any preliminary data, no formal sample
size calculation was performed.
The data was expressed as Mean ± SD, 95% CI if dis-
tributed normally and was analysed using One-way
ANOVA followed by Tukey’s post-hoc test. The data
was expressed as Median (Range) if not normally distrib-
uted and was analysed using Kruskal Wallis followed by
Dunn’s post-hoc test. Graphpad Instat software, version
3.06 was used for all analyses. The level of significance
for all analysis was taken as p<0.05. Two prakriti types







Kapha-Pitta 72 (35.67-98)for statistical analysis because of too few values in these
groups.Results
A total of 137 participants were recruited in the study.
The distribution of these volunteers according to Prak-
riti along with their demographic data is shown in
Table 1. The age and sex distribution of the participants
amongst the 3 prakrti types was comparable. Interest-
ingly, the BMI in vata-pitta prakriti was significantly
less as compared to kapha-pitta prakriti.
Although the vata-pitta prakriti individuals had the
maximum MPA as compared to other prakriti indivi-
duals (Table 2) this was not statistically significant. After
incubation with 2.5 or 5μM aspirin, % MPA in all prak-
riti types was comparable.
The largest change (dMPA) in the MPA after aspirin
was noted in the vata-pitta prakriti individuals followed
by those with kapha-vata and pitta-vata prakriti. Indivi-
duals with pitta-kapha and kapha-prakriti showed the
least inhibition of platelets at 2.5μM concentration. This
was significantly less than that in individuals with vata-
pitta prakriti (p<0.05). However, at 5μM aspirin, no dif-
ference was observed amongst prakriti types suggesting
that a plateau effect was reached with aspirin (Table 3).Discussion
We found in our cohort of normal healthy individuals
that platelet aggregation induced by ADP and the inhibi-
tory effect of aspirin differed according to prakriti. Thus,
vata-pitta prakriti individuals had the maximum MPA
as compared to other prakriti types. These individuals
also demonstrated largest dMPA after exposure to
2.5μM aspirin.
According to Ayurveda, Vata dosha is reported to be
responsible for a quick response or rapid movement,
whereas Pitta dosha is described as the dosha respon-
sible for metabolic activities (platelet aggregation occurs
secondary to tremendous enzymatic activity within and
around the platelets). These properties of doshas prob-
ably are also reflected in cellular responses. In our study
too the vata-pitta prakriti individuals had the maximum
platelet aggregation.(%MPA) (n=137) with or without aspirin [Median (Range)]
With Aspirin 2.5μM With Aspirin 5μM
52 (44-59) 55.33 (28-70)
49 (32-91) 51.50 (25.67-79)
58.17 (14-88.33) 48 (5-78)
50.50 (29-84) 44 (20-60)
51.50 (44-57) 41.17 (38-48)
51.67 (22-86) 40 (14.67-68)
Table 3 dMPA according to prakriti (n=137) [Median
(Range)]
Prakriti Concentrations of Aspirin
2.5μM 5μM
Vata-Kapha 29 (13-44) 29.17 (23-32)
Vata-Pitta 31.83 (3-57) 27.83 (11-51)
Pitta-Kapha 18 (3-48)* 27.33 (14-64)
Pitta-Vata 19.33 (12-40) 29.5 (21.33-49)
Kapha-Vata 22.67 (18.67-38) 32.83 (28-44)
Kapha-Pitta 16.67 (6-60)* 27.33 (9-71)
*p<0.05 as compared to vata-pitta prakriti using Kruskal-Wallis test followed by
Dunn’s post-test.
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lowers the aggregatory response. According to Ayurveda,
Kapha dosha leads to slow metabolism [5] which may
be reflected as a slower platelet aggregatory response.
Interestingly, our study highlights the subjective nature
of prakriti analysis indicating it is difficult to quantify
the influence of each dosha on the platelet response ob-
jectively e.g. pitta-kapha prakriti participants had a me-
dian MPA of 78 with a range of as low as 20 (perhaps
this participant had a higher kapha influence) to as high
as 115 (perhaps having higher pitta influence), while
individuals with the kapha-pitta prakriti (who have
combination of the same 2 doshas in different propor-
tions) had a median MPA of 72 with a range of only
35.67 to 98 suggesting that the dominant kapha dosha
in these participants tended to keep the aggregatory re-
sponse low on the whole. These findings suggest that
the predominant dosha determining prakriti might be
playing major role in the process of platelet aggregation.
However, these findings need to be confirmed in a larger
sample size with thorough quantitative analysis of prak-
riti determining doshas.
It is also important to note that ADP induced platelet
aggregation is a complex process in vivo, influenced by
various factors including levels of endogenous ADP,
cGMP and Arachidonic acid, blood viscosity [13] and
family history [14]. Therefore, the results of our study
may not reflect the in vivo situation.
ADP is known to be central amongst agonists of plate-
let aggregation that act upon surface expressed G
protein-coupled receptors P2Y1 and P2Y12. A recent
study [15] has demonstrated that P2Y12 H2 haplotype is
associated with the maximal aggregation response to
ADP [14]. Intra-individual differences in anti-platelet ef-
fect of aspirin have also been reported and association of
these differences with polymorphisms in the genes co-
ding for cyclo-oxygenase-1 (COX-1) and several platelet
glycoprotein (GP) receptors have also been studied [16].
Patwardhan et al [17] have shown that the extensive
metabolizer (EM) genotype of the drug metabolizingenzyme CYP2C19 (*1/*3) was found only in Pitta Prakriti.
The higher metabolic capacity of the pitta prakriti is simi-
lar to the higher platelet aggregation associated with pitta
in our study. It would be therefore interesting to study
whether the differences we observed in the present study
are due to the genetic variations amongst prakriti types.
A possible limitation of our study is unequal number of
individuals in different prakriti types and the small sample
size (n=4) in vata-kapha and kapha-vata types, Further,
there is evidence that the inter-individual differences in
platelet aggregatory response to ADP are more pro-
nounced at lower concentrations of ADP (1, 2 or 5 μM)
[15]. Hence, to detect the variations in %MPA amongst
prakriti subtypes, study of platelet aggregation using 1 and
2 μM ADP may prove more useful.
A recent study has shown that there is association be-
tween blood group of individual and risk of heart disease
[18]. Although we have not done blood grouping of volun-
teers recruited in our study, it would be worth exploring
whether blood groups have any association with Prakriti
as well. This association can prove an important bridge
between Ayurvedic and modern medical concepts.
The findings of our study however can have implications
with respect to pharmacogenomics & study of dose-
response relationships. These findings can also prove use-
ful for the randomization in clinical trial design, as
randomization would be best within the specific prakriti
or dosha predominant sub-groups than across an aggre-
gated population.Conclusions
Our study for the first time documents prakriti related
variations in platelet aggregation response in healthy
individuals.Additional file
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